Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL-Reference-Cited by-同舟云学术

Oncogene-independent BCR-like signaling adaptation confers drug resistance in Ph-like ALL

Published:2020-06-02 Issue:7 Volume:130 Page:3637-3653
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Hurtz Christian^ORCID,Wertheim Gerald B.,Loftus Joseph P.,Blumenthal Daniel^ORCID,Lehman Anne,Li Yong,Bagashev Asen^ORCID,Manning Bryan,Cummins Katherine D.^ORCID,Burkhardt Janis K.,Perl Alexander E.^ORCID,Carroll Martin^ORCID,Tasian Sarah K.^ORCID

Funder

Alex’s Lemonade Stand Foundation

American Society of Hematology

National Institutes of Health

Children’s Oncology Group Research Foundation

Rally Foundation for Childhood Cancer Research

Simutis Family Childhood Leukemia Research Foundation

National Cancer Institute

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/134424/files/pdf

Reference66 articles.

1. Adults with Philadelphia chromosome–like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis

2. Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults

3. High Frequency and Poor Outcome of Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia in Adults

4. Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia

5. Outcomes of Children With BCR-ABL1–Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increased AID results in mutations at the CRLF2 locus implicated in Latin American ALL health disparities;Nature Communications;2024-07-27

2. Mutation and cell state compatibility is required and targetable in Ph+acute lymphoblastic leukemia minimal residual disease;2024-06-10

3. Central role of the mTORC1 pathway in glucocorticoid activity against B-ALL cells;Blood Neoplasia;2024-06

4. Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain;Blood;2024-05-23

5. Acute lymphoblastic leukemia in young adults: which treatment?;Hematology;2023-12-08